Post-licensure safety surveillance of 23-valent pneumococcal polysaccharide vaccine in the Vaccine Adverse Event Reporting System (VAERS), 1990-2013.

Elaine R Miller,Pedro L Moro,Maria Cano,Paige Lewis,Marthe Bryant-Genevier,Tom T Shimabukuro

Vaccine（2016）

引用 15|浏览0

暂无评分

摘要

•No new or unexpected safety concerns were identified after Pneumovax®23 vaccine.•Fever and injection site reactions were the most commonly reported adverse events.•Cellulitis was one of the most commonly reported serious adverse events.

查看译文

关键词

23-Valent pneumococcal polysaccharide vaccine,Vaccines,Immunizations,Vaccine safety,Surveillance,Vaccine Adverse Event Reporting System (VAERS)

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要